Short Interest in XOMA Co. (NASDAQ:XOMA) Expands By 23.4%

XOMA Co. (NASDAQ:XOMA) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 139,000 shares, an increase of 23.4% from the November 30th total of 112,600 shares. Based on an average daily volume of 29,100 shares, the short-interest ratio is presently 4.8 days.

Analyst Upgrades and Downgrades

XOMA has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $123.00 target price on shares of XOMA in a research report on Friday, December 13th. StockNews.com lowered XOMA from a “hold” rating to a “sell” rating in a research note on Friday.

Insider Buying and Selling

In related news, CEO Owen Hughes sold 21,881 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the transaction, the chief executive officer now owns 34,979 shares of the company’s stock, valued at $1,047,621.05. This represents a 38.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Barclays PLC lifted its position in XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 8,447 shares during the period. Geode Capital Management LLC lifted its holdings in shares of XOMA by 0.6% during the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after purchasing an additional 1,138 shares during the last quarter. State Street Corp boosted its position in shares of XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after purchasing an additional 1,754 shares in the last quarter. BNP Paribas Financial Markets increased its position in XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 795 shares in the last quarter. Finally, Ellsworth Advisors LLC purchased a new position in XOMA during the third quarter valued at $516,000. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Trading Down 3.6 %

NASDAQ XOMA opened at $26.30 on Monday. The stock has a market cap of $309.89 million, a P/E ratio of -7.56 and a beta of 0.88. XOMA has a fifty-two week low of $18.24 and a fifty-two week high of $35.00. The stock has a 50 day simple moving average of $29.76 and a two-hundred day simple moving average of $27.87. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.